MUSIC: "Our World" theme
Straight ahead on "Our World" ... A new campaign against drug-resistant tuberculosis ... the songs of insects ... and going inside your head to see why doing good feels good.
GRAFMAN: So we thought, 'Let's focus on this particular kind of behavior because these other species tend not to be particularly altruistic, whereas humans tend to do this a lot.'"
Those stories, this year's winner of the World Food Prize, and more. I'm Art Chimes. Welcome to VOA's science and technology magazine, "Our World."
The World Health Organization and the Stop TB Partnership Thursday launched a $2 billion campaign to fight drug-resistant tuberculosis and save as many as 134,000 lives a year.
The WHO says there are an estimated nine million new cases of tuberculosis each year. Most cases can be treated with established drugs, but about one in twenty doesn't respond to the usual treatment. The head of the WHO's Stop TB Department, Mario Raviglione, says those patients then require so-called second-line drugs that are more more expensive and harder to use.
RAVIGLIONE: "If then, a patient at a certain point develops a form of TB that is not just multi-drug resistant, i.e. resistant to the basic treatment, but also now resistant to additional, second-line drugs, you are facing what is called XDR-TB or extensively drug-resistant TB."
The drug resistant varieties of tuberculosis have emerged in part because patients sometimes don't follow through with their treatment, which continues long after symptoms have disappeared. That gives TB bacteria a chance to regroup and develop resistance. That's one reason why treatment of TB patients needs to be managed carefully, says the WHO's Paul Nunn.
NUNN: "Drug resistance occurs when basic TB control is not sufficiently invested in, when the use of drugs is not properly done, when there is poor management of those drugs. And, also when the conditions are right for the transmission of TB, including drug-resistant TB around health facilities, around airplanes, buses, whatever."
Tuberculosis is particularly dangerous for patients who have a compromised immune system, notably people with HIV/AIDS.
The World Health Organization wants all patients with drug-resistant tuberculosis to have access to treatment by 2015.
Determining the right dosage for a vaccine can be tricky. You want to get enough vaccine to stimulate the production of antibodies against the disease, but too much would be wasteful and possibly harmful.
The issue could be critical in the case of a sudden outbreak of disease, when there is a surge of demand. That could be the scenario if the deadly H5N1 strain of avian flu mutates to allow the bug to be easily spread from person to person. So scientists are trying to assess the effectiveness of a smaller dose of vaccine ? which would allow the available amount of vaccine to be used to protect more people.
Our story, based on a study published in the journal PLoS Medicine, was written by Adriana Salerno and is read by Veronique LaCapra.
LaCAPRA: Countries around the world are preparing for a global outbreak of avian flu. Although the H5N1 influenza virus is always mutating, Steven Riley, from the University of Hong Kong, says researchers are developing and stockpiling vaccines anyway.
RILEY: "So this is a human vaccine, which is formulated and targeted against the current avian strain. The rationale is that there will be a very small mutation within the strain that will allow it to cause human disease and to cause human infection and that if you formulate the vaccine against the current strain they'll be available and ready to go when we have a human pandemic."
LaCAPRA: Even with this effort, scientists think there may not be enough vaccine for everyone, so a natural question arises: who gets vaccinated? The standard procedure is for certain high-risk groups to get the vaccine first: healthcare workers, emergency personnel, children and the elderly. Riley and his colleagues propose a radically different approach: use lower doses and vaccinate more people.
RILEY: "And our findings are there are likely to be substantial reductions in the proportion of people who are likely to be infected if you give a lower dose to more people than if you give the maximum tested dose to fewer people. Our estimate is that if 160 out of the 300 million people in the US were given the lower dose rather than 20 out of the 300 million given the maximum protected dose, you could be talking about 27 million fewer infections."